NORTH CHICAGO, Ill., May 14, 2025 - AbbVie Inc. $(ABBV)$ has announced that EMRELIS™ (telisotuzumab vedotin-tllv) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, who have previously undergone systemic therapy. This approval marks a significant milestone as EMRELIS is the first and only treatment available for this specific group of NSCLC patients, who often face limited treatment options and poor prognosis. The FDA had earlier granted EMRELIS Breakthrough Therapy Designation based on the Phase 2 LUMINOSITY study data. The drug is currently being further evaluated in a randomized Phase 3 confirmatory global study, TeliMET NSCLC-01, with patient enrollment underway. Additionally, the FDA has approved the Roche VENTANA® MET (SP44) RxDx Assay as the companion diagnostic to identify eligible patients for EMRELIS treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.